BACKGROUND: Radiation-associated angiosarcoma (RAAS) is a devastating disease occasionally observed in breast cancer patients treated with radiation. Due to its rarity, our knowledge-of disease risk factors, epidemiology, treatment, and outcome-is extremely limited. Therefore, we sought to identify clinicopathologic factors associated with local and distant recurrence and disease-specific survival (DSS). METHODS: Radiation-associated angiosarcoma was defined as pathologically confirmed breast or chest wall angiosarcoma arising within a previously irradiated field. A comprehensive search of our institutional tumor registry (1/1/93 through 2/28/11) was used to identify patients (n = 95 females). Patient, original tumor, RAAS treatment, and outcome variables were retrospectively retrieved and assembled into a database. RESULTS: The median follow-up for all RAAS patients was 10.3 (range, 2.4-31.8) years. The latency period following radiation exposure ranged from 1.4 to 26 (median, 7) years. One-year and 5-year DSS rates were 93.5 and 62.6 %, respectively. Reduced risk of local recurrence was observed in patients who received chemotherapy (P = 0.0003). In multivariable analysis, size was found to be an independent predictor of adverse outcome (P = 0.015). CONCLUSIONS: Our study demonstrates that RAAS exhibits high recurrence rates. It also highlights the need for well-designed, multicenter, clinical trials to inform the true utility of chemotherapy in this disease.
BACKGROUND: Radiation-associated angiosarcoma (RAAS) is a devastating disease occasionally observed in breast cancerpatients treated with radiation. Due to its rarity, our knowledge-of disease risk factors, epidemiology, treatment, and outcome-is extremely limited. Therefore, we sought to identify clinicopathologic factors associated with local and distant recurrence and disease-specific survival (DSS). METHODS: Radiation-associated angiosarcoma was defined as pathologically confirmed breast or chest wall angiosarcoma arising within a previously irradiated field. A comprehensive search of our institutional tumor registry (1/1/93 through 2/28/11) was used to identify patients (n = 95 females). Patient, original tumor, RAAS treatment, and outcome variables were retrospectively retrieved and assembled into a database. RESULTS: The median follow-up for all RAAS patients was 10.3 (range, 2.4-31.8) years. The latency period following radiation exposure ranged from 1.4 to 26 (median, 7) years. One-year and 5-year DSS rates were 93.5 and 62.6 %, respectively. Reduced risk of local recurrence was observed in patients who received chemotherapy (P = 0.0003). In multivariable analysis, size was found to be an independent predictor of adverse outcome (P = 0.015). CONCLUSIONS: Our study demonstrates that RAAS exhibits high recurrence rates. It also highlights the need for well-designed, multicenter, clinical trials to inform the true utility of chemotherapy in this disease.
Authors: Marianne A A de Jong; Sabine Oldenborg; S Bing Oei; Vanessa Griesdoorn; M Willemijn Kolff; Caro C E Koning; Geertjan van Tienhoven Journal: Cancer Date: 2011-06-28 Impact factor: 6.860
Authors: S M Pierce; A Recht; T I Lingos; A Abner; F Vicini; B Silver; A Herzog; J R Harris Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: Matthew G Fury; Cristina R Antonescu; Kimberly J Van Zee; Murray F Brennan; Robert G Maki Journal: Cancer J Date: 2005 May-Jun Impact factor: 3.360
Authors: Steven D Billings; Jesse K McKenney; Andrew L Folpe; Michael C Hardacre; Sharon W Weiss Journal: Am J Surg Pathol Date: 2004-06 Impact factor: 6.394
Authors: Anouk J M Rombouts; Jonathan Huising; Niek Hugen; Sabine Siesling; Philip Martin Poortmans; Iris D Nagtegaal; Johannes H W de Wilt Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Sean P Dineen; Christina L Roland; Rachel Feig; Caitlin May; Shouhao Zhou; Elizabeth Demicco; Ghadah Al Sannaa; Davis Ingram; Wei-Lein Wang; Vinod Ravi; Ashleigh Guadagnolo; Dina Lev; Raphael E Pollock; Kelly Hunt; Janice Cormier; Alex Lazar; Barry Feig; Keila E Torres Journal: Ann Surg Oncol Date: 2015-03-06 Impact factor: 5.344
Authors: Joshua Herb; Ugwuji N Maduekwe; Neha Goel; Laura H Rosenberger; Philip M Spanheimer Journal: J Am Coll Surg Date: 2022-05-01 Impact factor: 6.532
Authors: Raffaella Benevento; Francesco Carafa; Domenico Di Nardo; Gianluca Pellino; Antonia Letizia; Marianna Taddeo; Antonio Gambardella; Silvestro Canonico; Antonio Santoriello Journal: Int J Surg Case Rep Date: 2015-06-06